Skip to main content

SGX and Serono to Collaborate on Kinase and Phosphatase Drugs

NEW YORK, March 23 (GenomeWeb News) - Structural Genomix and Serono will collaborate on developing drugs that target kinases and phosphatases, SGX said today.


Under the agreement, SGX will use its X-ray crystallography-based approach, called Fragments of Active Structures, to generate lead compounds against kinase and phosphatase targets provided by Serono. Geneva, Switzerland-based Serono will develop and commercialize drug candidates resulting from the collaboration.


In return, San Diego-based SGX will receive up to $68 million in upfront and research fees and milestone payments. In addition, it will obtain royalties from sales of drugs.


SGX's FAST approach combines screening of lead-like drug fragments using X-ray crystallography with computational design and chemical synthesis.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.